Alport Syndrome — Hereditary Nephritis, Hearing Loss & Genetic Diagnosis

Key Points

• Persistent glomerular hematuria plus family history, hearing loss, or characteristic ocular findings should prompt evaluation for COL4A3–COL4A5 disease.
• Genetic testing is increasingly the preferred confirmatory strategy and clarifies inheritance, prognosis, and family risk.
• Proteinuria and declining eGFR are stronger severity markers than hematuria alone.
• ACE inhibitors or ARBs are the core kidney-protective therapy and should be started early in patients at meaningful risk of progression.
• Women with X-linked disease and heterozygous COL4A3/COL4A4 patients are not automatically benign carriers.
• Sensorineural hearing loss and anterior lenticonus are high-yield extrarenal clues.
• Related potential kidney donors need genetic evaluation before donation.
• Immunosuppression is not routine therapy for genetically mediated Alport nephropathy.

Algorithm

1. Confirm persistent glomerular hematuria with urine microscopy and quantify albuminuria/proteinuria.
2. Review pedigree for hematuria, kidney failure, hearing loss, and known collagen IV disease.
3. Assess blood pressure, serum creatinine/eGFR, urine albumin-to-creatinine ratio, hearing, and ocular history.
4. Order a COL4A3/COL4A4/COL4A5-inclusive genetic panel when the phenotype is compatible.
5. Use kidney biopsy with EM/collagen IV staining when genetic testing is unavailable, nondiagnostic, or another glomerular disorder remains plausible.
6. Start ACE inhibitor or ARB according to genotype and albuminuria/proteinuria risk; titrate with potassium and creatinine monitoring.
7. Arrange audiology, ophthalmology, genetic counseling, and cascade testing of relatives.
8. Plan kidney-replacement therapy and transplant evaluation if progressive CKD reaches advanced stages.

Clinical Synopsis & Reasoning

Alport syndrome should be considered when persistent glomerular hematuria occurs in a patient with a family history of hematuria, chronic kidney disease, kidney failure, hearing loss, or a known COL4A3, COL4A4, or COL4A5 variant. The disease results from abnormal type IV collagen in the glomerular basement membrane and in selected cochlear and ocular structures. X-linked disease due to COL4A5 is the classic form, but autosomal recessive, autosomal dominant, and digenic patterns occur. The old distinction between “Alport syndrome” and “thin basement membrane nephropathy” is increasingly less useful because heterozygous COL4A3/COL4A4 disease can still carry clinically meaningful kidney risk.

The renal phenotype often begins with microscopic hematuria in childhood. Proteinuria, hypertension, and progressive loss of glomerular filtration emerge later and are stronger predictors of long-term kidney outcome than hematuria alone. Gross hematuria may occur with intercurrent infections. Sensorineural hearing loss classically affects high frequencies and can emerge in late childhood or adolescence. Ocular clues include anterior lenticonus, dot-and-fleck retinopathy, and other characteristic retinal changes. These extrarenal findings strongly support the diagnosis but are not required.

The key diagnostic pivot is recognizing a hereditary glomerular process rather than repeatedly labeling the patient as having nonspecific hematuria. Urine microscopy may show dysmorphic red cells, while protein quantification establishes disease severity. Serologic testing for immune glomerulonephritis is guided by the phenotype rather than performed indefinitely. Current practice increasingly favors molecular testing with a panel that includes COL4A3, COL4A4, and COL4A5 because genotype clarifies inheritance, prognosis, family screening, transplant-donor counseling, and in many patients avoids kidney biopsy. When biopsy is performed, electron microscopy may show thinning, thickening, lamellation, and splitting of the GBM; collagen IV immunostaining can support the diagnosis.

A major reasoning error is to assume that a female with an X-linked variant or a heterozygous COL4A3/COL4A4 variant is merely a “carrier.” These patients can develop proteinuria, hypertension, and kidney failure and require surveillance. Another important distinction is between Alport syndrome and IgA nephropathy, inherited FSGS, postinfectious hematuria, and urologic causes. Family history, persistent dysmorphic hematuria, hearing/ocular features, and genetic testing usually move the case toward the correct branch.

Treatment Strategy & Disposition

Management is aimed at slowing progression of proteinuric kidney disease, identifying extrarenal complications, and preventing harm to affected relatives. Renin-angiotensin system blockade with an ACE inhibitor or ARB is the central kidney-protective therapy. In higher-risk genotypes, particularly males with X-linked disease and patients with autosomal recessive disease, treatment is often started early rather than waiting for advanced proteinuria. In other groups, microalbuminuria or overt proteinuria is a strong trigger for therapy. Blood pressure, potassium, creatinine, and albuminuria should be followed after initiation and during dose escalation.

There is no role for immunosuppression simply because hematuria or proteinuria is present. Hearing loss is managed with audiology surveillance and hearing aids when needed. Ophthalmologic assessment is useful for diagnostic support and for visual complications such as anterior lenticonus. Patients who progress to kidney failure are candidates for kidney transplantation; outcomes are generally excellent, although anti-GBM nephritis after transplant is a rare complication. Potential living related donors require careful genetic assessment because a relative with a pathogenic COL4A3/COL4A4/COL4A5 variant may be an unsuitable donor even if kidney function appears normal.

Genetic counseling is part of treatment, not an optional add-on. Once a pathogenic variant is identified, cascade testing of first-degree relatives can identify patients before proteinuria or loss of kidney function develops. Pregnancy counseling is also relevant because RAAS-blocking drugs are teratogenic and must be stopped before pregnancy, while kidney disease severity influences maternal and fetal risk.

Disposition is usually outpatient, but accelerated kidney injury, nephrotic-range proteinuria with complications, severe hypertension, suspected rapidly progressive glomerulonephritis, or a transplant-related complication warrants higher-acuity evaluation. Long-term follow-up should integrate nephrology, audiology, ophthalmology, and genetics rather than treating each manifestation in isolation.

Epidemiology / Risk Factors

• X-linked Alport syndrome from COL4A5 variants is the most recognized inheritance pattern.
• Autosomal recessive and autosomal dominant COL4A3/COL4A4 disease broaden the phenotype beyond the traditional textbook description.
• Clinical severity varies substantially by genotype and sex.
• Persistent familial hematuria is often the earliest clue and may precede proteinuria by years.

Investigations

Genotype-Phenotype Clues

Pharmacology

Prognosis / Complications

• Earlier onset of proteinuria, male X-linked disease, and autosomal recessive disease are generally associated with higher kidney-failure risk.
• RAAS blockade can materially delay progression to kidney failure.
• Hearing impairment can progress even when kidney function is preserved.
• Transplant outcomes are usually favorable, but lifelong nephrology follow-up remains necessary.

Patient Education / Counseling

• Explain that Alport syndrome is inherited and may affect relatives who currently feel well.
• Teach the importance of urine protein, blood pressure, and kidney-function surveillance rather than focusing only on hematuria.
• Review hearing and vision symptoms and the value of scheduled screening.
• Discuss medication changes before pregnancy and avoidance of nephrotoxins when possible.
• Encourage cascade genetic testing for first-degree relatives once a pathogenic family variant is known.

Notes

Alport syndrome is best approached as a genetically defined spectrum rather than a single rigid phenotype. The most important clinical shift is to identify affected patients before advanced proteinuria or kidney failure develops. Molecular diagnosis allows the clinician to move from repeated nonspecific hematuria workups to targeted kidney protection, family testing, and reproductive counseling.

The classic board-style clue is hematuria plus sensorineural hearing loss, but real-world disease is frequently subtler. A patient may have isolated hematuria for years, a woman with X-linked disease may develop progressive CKD, and heterozygous COL4A3/COL4A4 disease can be clinically important. The decision point is therefore not whether the patient perfectly matches the historical triad; it is whether the pattern justifies collagen IV genetic evaluation and kidney-protective treatment.

References

1. GeneReviews — Alport Syndrome (updated 2025) — Link
2. Savige J, et al. Guidelines for Genetic Testing and Management of Alport Syndrome. CJASN. 2022. — Link